--- title: "Vertex Pharmaceuticals (VRTX) Following Fresh CASGEVY Data Has Its Valuation Back In Focus" type: "News" locale: "en" url: "https://longbridge.com/en/news/290988748.md" description: "Vertex Pharmaceuticals (VRTX) is regaining market focus following positive Phase 3 data for its gene-editing therapy CASGEVY in pediatric patients. The stock has seen a 10.15% one-month return, trading around $480. Analysis suggests the stock is undervalued with a fair value of $547.72, driven by pipeline diversification and intrinsic discount. However, risks remain due to reliance on cystic fibrosis products and potential pricing pressures." datetime: "2026-06-26T16:04:11.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/290988748.md) - [en](https://longbridge.com/en/news/290988748.md) - [zh-HK](https://longbridge.com/zh-HK/news/290988748.md) --- # Vertex Pharmaceuticals (VRTX) Following Fresh CASGEVY Data Has Its Valuation Back In Focus Vertex Pharmaceuticals (VRTX) is back in focus after fresh Phase 3 data for its gene editing therapy CASGEVY in children aged 5 to 11 with severe sickle cell disease and transfusion dependent beta thalassemia. See our latest analysis for Vertex Pharmaceuticals. Recent clinical headlines around CASGEVY and suzetrigine appear to have coincided with stronger interest in Vertex Pharmaceuticals, with a 10.15% 1 month share price return and a 137.47% 5 year total shareholder return suggesting momentum built over the longer term. If this kind of pipeline driven story interests you, it can be useful to see what other healthcare stocks are attracting attention through AI and data led treatments, starting with our screener for 39 healthcare AI stocks Vertex Pharmaceuticals now trades around US$480, backed by a 41.3% intrinsic discount from a DCF model and a double digit 3 year total return. Is the stock still underappreciated, or is the market already pricing in the next leg of growth? ## Most Popular Narrative: 12.3% Undervalued Vertex Pharmaceuticals closed at $480.18, while the most followed narrative anchors fair value at $547.72, framing today’s price against modeled long term earnings power. > _Vertex's pipeline diversification, including programs in pain, kidney, and type 1 diabetes, leverages global advances in genomic and gene-editing technologies, positioning the company to capture long-term growth from accelerating personalized and precision medicine adoption, supporting both revenue and long-term margin expansion._ _Read the complete narrative._ Curious what sits behind that valuation gap for Vertex Pharmaceuticals? The narrative leans on steady top line expansion, rising margins, and a future earnings multiple that assumes investor confidence holds. The exact growth cadence and profit profile it uses might surprise you. **Result: Fair Value of $547.72 (UNDERVALUED)** Have a read of the narrative in full and understand what's behind the forecasts. However, Vertex Pharmaceuticals still leans heavily on its cystic fibrosis portfolio, and setbacks or pricing pressure across newer programs could quickly challenge the narrative around its current growth. Find out about the key risks to this Vertex Pharmaceuticals narrative. ## Next Steps With the narrative around Vertex Pharmaceuticals leaning positive, this is a good moment to move quickly and test the optimism against your own research. To see what those potential upsides look like in more detail, take a look at the 3 key rewards. ## Looking for more investment ideas beyond Vertex Pharmaceuticals? If Vertex Pharmaceuticals has you thinking about what else could strengthen your portfolio, this is the moment to widen your search before the next move passes you by. - Target resilience by scanning companies that show up in the solid balance sheet and fundamentals stocks screener (48 results) and see which businesses pair strong finances with staying power. - Hunt for potential mispricings using the 43 high quality undervalued stocks and spot stocks where fundamentals and current prices appear out of sync. - Secure your income stream by reviewing the 9 dividend fortresses and identify companies offering higher yields with an eye on consistency. _This article by Simply Wall St is general in nature. **We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.** It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._ ### **New:** Manage All Your Stock Portfolios in One Place We've created the **ultimate portfolio companion** for stock investors, **and it's free.** • Connect an unlimited number of Portfolios and see your total in one currency • Be alerted to new Warning Signs or Risks via email or mobile • Track the Fair Value of your stocks Try a Demo Portfolio for Free ### Related Stocks - [VRTX.US](https://longbridge.com/en/quote/VRTX.US.md) ## Related News & Research - [Vertex EVP, CMO Carmen Bozic sells 1,020 Vertex shares for $471,413.4](https://longbridge.com/en/news/290603896.md) - [Vertex EVP, CMO Carmen Bozic sells 4,062 Vertex shares worth $1.83 million](https://longbridge.com/en/news/290100318.md) - [Zevra publishes Phase 2/3 pediatric substudy showing MIPLYFFA tolerability in infants with Niemann-Pick type C](https://longbridge.com/en/news/290556169.md) - [Taysha Gene Therapies to present REVEAL Phase 1/2 data for Rett gene therapy TSHA-102 at 2026 IRSF meeting](https://longbridge.com/en/news/290873833.md) - [Spectral Medical says FDA files PMA application for PMX therapy](https://longbridge.com/en/news/290819659.md)